(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Electronics giant LG on ...
The Institute for Clinical and Economic Review said it cannot fairly judge Lykos Therapeutics’ MDMA-assisted ...
GoodRx said on Wednesday that it has won back its relationship with Kroger to offer prescription discount coupons to people ...
The cardiovascular benefits of Novo Nordisk’s blockbuster weight loss drug Wegovy are not dependent on the amount of weight ...
Merck KGaA’s revenue from its CDMO arm dropped in the first quarter due to customer destocking, but it still expects business ...
Eisai is hoping to grow Leqembi sales 13-fold to around $360 million in fiscal year 2024, as it plans “aggressive investment” and looks to expand its Biogen-partnered Alzheimer’s drug’s market both in ...
Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California ...
Less than a month after revealing pipeline cuts amid disappointing gene therapy sales, BioMarin is now also downsizing its team. The biotech said it will lay off about 170 workers worldwide on the ...
Eisai heads to FDA with subcutaneous version of Alzheimer’s treatment developed with Biogen
Eisai and Biogen said Tuesday that they started an application for an under-the-skin maintenance dosing version ...
Ascendis Pharma will likely wait three more months to get an answer from the FDA on the review of its hypoparathyroidism drug ...
WuXi AppTec is cutting a small number of roles at a facility in St. Paul, MN, a company spokesperson told Endpoints News in ...
Pliant Therapeutics unveiled more efficacy data from a small mid-stage trial of its lead candidate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results